Twist Bioscience : June Corporate Presentation
TWST
Published on 06/03/2025 at 10:41
Writing the Future
JU N E 2 0 2 5
Legal Disclaimers
This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, annual financial guidance for fiscal 2025 and for the third and fourth quarters of fiscal 2025, statements regarding Twist Bioscience's revenue goals, path to profitability, future growth, expansion, ability and timing to increase gross margin, market share gains and Twist Bioscience's other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist Bioscience's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to Twist Bioscience's business in general, see Twist Bioscience's risk factors set forth in
Twist Bioscience's Annual Report on Form 10-K filed with the SEC on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
The presentation also contains supplemental financial information determined by methods other than in accordance with U.S. generally accepted accounting principles ("GAAP"). A reconciliation of these non-GAAP financial measures may be found starting on page 29of this presentation.
| PROPRIETARY
MORE
Products
MORE
Customers
MORE
Applications
MORE
Markets
PROTEINS
DNA
One chip
Unprecedented scale, many opportunities for cost efficient expansion
3 | TWIST BIOSCIENCE
RNA
ter of Growth
Our Next Chap
Commercial Execution
$1 Billon
In Revenue
Strong Differentiation
Proven Technology
Culture of Innovation
Understanding of End Markets
4 | TWIST BIOSCIENCE
| PROPRIETARY
Crossing the Threshold to Profitability
Continued revenue and margin growth
Strong operational and commercial execution
Market and wallet share expansion
Growing markets
Platform enhancements
and new products
Adjusted EBITDA Breakeven
Disclaimer
Twist Bioscience Corporation published this content on June 03, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 03, 2025 at 14:40 UTC.